News

Neoadjuvant Pembrolizumab Yields High Response Rates Among Patients With Microsatellite Instability High/Deficient Mismatch Repair Colorectal Cancer

01/26/2023

Allison Casey ;

In a phase 2 trial, neoadjuvant pembrolizumab was safe and yielded high response rates among patients with MSI-H/dMMR solid tumors including colorectal cancer, with implications for organ-sparing strategies.

In a phase 2 trial, neoadjuvant...

01/26/2023

Oncology

Videos

Addition of Bevacizumab to Trifluridine/Tipiracil Improves OS Among Patients with Refractory Metastatic Colorectal Cancer

01/23/2023

At the 2023 ASCO Gastrointestinal Symposium, Josep Tabernero, MD, shared results from the phase 3 trial evaluating trifluridine/tipiracil plus bevacizumab for patients with refractory colorectal cancer.

At the 2023 ASCO...

01/23/2023

Oncology

Conference Coverage

Botensilimab Plus Balstilimab Demonstrated Durable Responses for Patients With Microsatellite Stable Colorectal Cancer

01/21/2023

Allison Casey ;

In an expanded phase 1a/1b study presented at 2023 ASCO Gastrointestinal Cancers Symposium, botensilimab plus balstilimab demonstrated durable clinical activity for patients with microsatellite stable colorectal cancer.

In an expanded phase 1a/1b study...

01/21/2023

Oncology

Conference Coverage

Long-Course Chemoradiation vs Short-Course Radiation Therapy for Organ Preservation Among Patients With Rectal Cancer

01/21/2023

Allison Casey ;

In a study presented at 2023 ASCO Gastrointestinal Cancers Symposium, long-course chemoradiation as total neoadjuvant therapy for patients with rectal cancer was associated with a numerically higher organ preservation rate than short-course...

In a study presented at 2023...

01/21/2023

Oncology

News

FDA Grants Accelerated Approval to Tucatinib With Trastuzamab for RAS Wild-Type HER2-Positive Colorectal Cancer

01/20/2023

Derek Cowsert ;

On January 19, 2023, the FDA approved tucatinib, in combination with trastuzumab, for adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer.

On January 19, 2023, the FDA...

01/20/2023

Oncology

News

Adagrasib Shows Antitumor Activity in Metastatic Colorectal Cancer With Mutant KRAS G12C

01/06/2023

Allison Casey ;

According to results of a phase 1/2 clinical trial, adagrasib showed clinical activity in patients with metastatic colorectal cancer with KRAS G12C mutations. This activity was greater when combined with cetuximab.

According to results of a phase...

01/06/2023

Oncology

News

Nivolumab Plus Low-Dose Ipilimumab Conveys Durable Benefit for Patients With MSI-H/dMMR Metastatic CRC

10/21/2022

Follow-up data from a phase 2 study confirmed the long-term benefit and tolerability of nivolumab plus low-dose ipilimumab for patients with MSI-H/dMMR metastatic colorectal cancer.

Follow-up data from a phase 2...

10/21/2022

Oncology

News

Laparoscopic Surgery Yielded Safety, Outcomes Comparable to Open Surgery for Patients With Low Rectal Cancer

10/03/2022

Allison Casey ;

Laparoscopic surgery was determined to have comparable safety and outcomes compared to open surgery for patients with low rectal cancer, according to a randomized clinical trial.

Laparoscopic surgery was...

10/03/2022

Oncology

Arvind Dasari, MD, MD Anderson Cancer Center

Videos

Fruquintinib Improves Survival for Patients With Heavily Pretreated Metastatic Colorectal Cancer

09/29/2022

Arvind Dasari, MD, discusses results from phase 3 FRESNO-2 trial which demonstrated a significant survival benefit with fruquintinib for patients with highly refractory metastatic colorectal cancer.

Arvind Dasari, MD, discusses...

09/29/2022

Oncology

Conference Coverage

Tucatinib Monotherapy and Tucatinib Plus Trastuzumab for Patients With HER2-Positive Metastatic Colorectal Cancer

09/15/2022

Allison Casey ;

Additional analyses from the phase 2 MOUNTAINEER study show that tucatinib monotherapy and tucatinib plus trastuzumab were well-tolerated following crossover among patients with HER2-positive colorectal cancer and the concurrent initiation of...

Additional analyses from the...

09/15/2022

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology